TheStreet Upgrades Aratana Therapeutics (PETX) to C-

TheStreet upgraded shares of Aratana Therapeutics (NASDAQ:PETX) from a d rating to a c- rating in a research note published on Wednesday.

A number of other equities research analysts also recently commented on the stock. HC Wainwright set a $10.00 price objective on shares of Aratana Therapeutics and gave the company a buy rating in a research report on Monday, November 5th. BidaskClub upgraded shares of Aratana Therapeutics from a hold rating to a buy rating in a research report on Tuesday, October 23rd. Zacks Investment Research upgraded shares of Aratana Therapeutics from a hold rating to a buy rating and set a $5.75 price objective for the company in a research report on Tuesday, September 11th. Finally, ValuEngine upgraded shares of Aratana Therapeutics from a sell rating to a hold rating in a research report on Monday, October 22nd. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $8.15.

Shares of NASDAQ:PETX opened at $6.61 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.17 and a quick ratio of 2.70. The stock has a market capitalization of $315.08 million, a P/E ratio of -6.81 and a beta of 1.95. Aratana Therapeutics has a 52 week low of $3.67 and a 52 week high of $7.28.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.03. The firm had revenue of $21.56 million during the quarter, compared to the consensus estimate of $5.70 million. Aratana Therapeutics had a negative net margin of 52.94% and a negative return on equity of 15.08%. On average, sell-side analysts anticipate that Aratana Therapeutics will post -0.25 earnings per share for the current fiscal year.

In other news, insider Ernst Heinen sold 19,308 shares of Aratana Therapeutics stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $6.95, for a total transaction of $134,190.60. Following the completion of the sale, the insider now directly owns 135,694 shares in the company, valued at approximately $943,073.30. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Peter Steven St sold 11,513 shares of Aratana Therapeutics stock in a transaction that occurred on Tuesday, October 30th. The shares were sold at an average price of $5.86, for a total transaction of $67,466.18. Following the sale, the insider now owns 562,720 shares of the company’s stock, valued at $3,297,539.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 106,513 shares of company stock valued at $660,966. Insiders own 5.30% of the company’s stock.

Several hedge funds have recently bought and sold shares of PETX. American Century Companies Inc. acquired a new stake in shares of Aratana Therapeutics during the 2nd quarter valued at approximately $195,000. MetLife Investment Advisors LLC acquired a new stake in shares of Aratana Therapeutics during the 3rd quarter valued at approximately $215,000. Bank of Montreal Can lifted its position in shares of Aratana Therapeutics by 152.9% during the 3rd quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock valued at $301,000 after acquiring an additional 31,053 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Aratana Therapeutics during the 2nd quarter valued at approximately $487,000. Finally, Northern Trust Corp lifted its position in shares of Aratana Therapeutics by 7.2% during the 2nd quarter. Northern Trust Corp now owns 489,766 shares of the biopharmaceutical company’s stock valued at $2,082,000 after acquiring an additional 32,773 shares during the period. Institutional investors own 64.78% of the company’s stock.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Further Reading: Balance Sheet

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply